• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis

tetano

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2021 Apr 8;8(7):ofab176.
doi: 10.1093/ofid/ofab176. eCollection 2021 Jul.
Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis


Elena G Gibson[SUP] 1 [/SUP], Melissa Pender[SUP] 2 [/SUP], Michael Angerbauer[SUP] 3 [/SUP], Craig Cook[SUP] 4 [/SUP], Barbara Jones[SUP] 4 [/SUP], Adam M Spivak[SUP] 2 [/SUP], Emily S Spivak[SUP] 2 5 [/SUP], Sankar Swaminathan[SUP] 2 5 [/SUP]



Affiliations

Abstract

We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS-CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution.

Keywords: COVID-19; SARS-CoV-2; humoral immunity; ocrelizumab.
 
You must log in or register to reply here.
Back
Top Bottom